Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
RESEARCH TOOLSreports
Bicycle Therapeutics (BCYC) Stock Forecast & Price Target
302 Followers
See the Price Targets and Ratings of:
BCYC Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BCYC Stock 12 Month Forecast
Average Price Target
$44.71
▲(104.90% Upside)
| Highest Price Target$60.00 | Average Price Target$44.71 | Lowest Price Target$32.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
JMP Securities
Reiterated
04/09/24
H.C. Wainwright
Reiterated
02/21/24
Canaccord Genuity
Reiterated
02/20/24
Leerink Partners
Reiterated
02/20/24
Morgan Stanley
Reiterated
12/19/23
Piper Sandler
Reiterated
11/03/23
B.Riley Financial
$33.00
Buy
51.24%
Upside
Upgraded
09/11/23
Bicycle Therapeutics upgraded to Buy from Neutral at B. RileyBicycle Therapeutics upgraded to Buy from Neutral at B. Riley
EF Hutton
$55.00
Buy
152.06%
Upside
Reiterated
04/19/23
EF Hutton Reiterates Buy on Bicycle Therapeutics, Maintains $55 Price Target
Unknown Analyst
Not Ranked
Goldman Sachs
―
Buy
―
Reiterated
05/05/23
Bicycle Therapeutics (BCYC): DKFZ collaboration further strengthens radio-conjugate optionality 5 May 2023 | 8:13PM BST BCYC reported Q1’23 results and provided a corporate update. Within the financials we note R&D expenses of $32m came in ~30% ahead of our forecast of $24m whilst SG&A was largely in line. In parallel to Q1 results, the company also announced a collaboration with the Center (DKFZ) to develop and discover Bicycle radio-conjugates (BRCs) in oncology with the collaboration yielding preclinical data for tumour targeting BRCs to date. The collaboration further strengthens BCYC’s radio-conjugate optionality following the Novartis collaboration announced in March (see our note here) the company now plans to initiate clinical development of its wholly owned BRCs by the end of 2024.
Best Analysts Covering Bicycle Therapeutics
Which Analyst Should I Follow If I Want to Buy BCYC and Sell After:
1 Month
3 Months
1 Year
2 Years
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BCYC Analyst Recommendation Trends
Rating
Oct 23
Nov 23
Dec 23
Feb 24
Apr 24
Strong Buy
9
9
14
19
14
Buy
1
2
1
3
3
Hold
2
1
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
12
17
24
18
Each month's total comprises the sum of three months' worth of ratings.
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
BCYC Financial Forecast
BCYC Stock Forecast FAQ
What is BCYC’s average 12-month price target, according to analysts?
Based on analyst ratings, Bicycle Therapeutics Ltd’s 12-month average price target is $44.71.
What is BCYC’s upside potential, based on the analysts’ average price target?
Bicycle Therapeutics Ltd has 104.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BCYC a Buy, Sell or Hold?
Bicycle Therapeutics Ltd has a conensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Bicycle Therapeutics Ltd’s price target?
The average price target for Bicycle Therapeutics Ltd is $44.71. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $32.00. The average price target represents 104.90% Increase from the current price of $21.82.
The highest analyst price target is $60.00 ,the lowest forecast is $32.00. The average price target represents 104.90% Increase from the current price of $21.82.
What do analysts say about Bicycle Therapeutics Ltd?
Bicycle Therapeutics Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of BCYC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.